14 results about "Overweight" patented technology

The present invention relates to a GLP-1- / GlP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GlP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The application discloses a traditional Chinese medicine composition for people with obesity and overweight of spleen deficiency and damp-heat type and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: Gualou 40-60 parts, Yiyiren 30-50 parts, Fuling 80-110 parts, Zhizi 10-20 parts, Renshen 1-5 parts and Huangjing 5-10 parts. The Gualou, Yiyiren and Fuling are used as monarch drugs to invigorate the spleen and eliminate dampness, the Zhizi is used as a minister drug to clear heat and drain dampness, the Renshen and Huangjing are used to tonify qi and nourish yin, support the root of spleen deficiency, and make up for the bitter cold of the Zhizi to hurt the stomach, so that the traditional Chinese medicine composition can achieve the functions of invigorating the spleen and eliminating dampness, clearing heat and tonifying qi, and treat the root and branch of the people with obesity and overweight of spleen deficiency and damp-heat type according to the pathogenesis characteristics of the spleen deficiency as the root and the damp-heat as the branch. The application has a simple formula, mild medicinal properties, and is suitable for long-term taking. The application further provides a preparation method of the traditional Chinese medicine composition, which can be prepared into a decoction, granules, capsules, tablets, pills or oral liquid, and has the advantages of simple preparation process, stable product quality and convenient taking.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

Disclosed herein is a preserved liquid pharmaceutical formulation comprising a amylin receptor agonist, a GLP-1 receptor agonist, a hydroxypropyl-substituted cyclodextrin, and one or more preservatives. The co-formulation can be used for medical treatment of subjects with: overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated co-morbidities; and cardiovascular disease.

This invention relates to the field of functional food technology, specifically to a solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects, and its preparation method. The solid beverage comprises the following ingredients by weight: 2-3 parts modified sodium alginate, 5-8 parts inulin, 2-4 parts orange peel, 3-6 parts red adzuki bean extract, 1.5-3 parts cassia seed extract, 1-2 parts bitter orange flower extract, 2-4 parts radish seed extract, 3-6 parts hawthorn, and 2-4 parts lotus leaf extract. This solid beverage with lipid-lowering, weight-loss, spleen-strengthening, and digestion-aiding effects has the functions of lowering lipids, promoting digestion, weight loss, and spleen strengthening. Combined with dietary fiber such as inulin and resistant dextrin, it helps maintain intestinal function. Modified sodium alginate improves emulsification and dissolving stability. This solid beverage can be used as an auxiliary conditioning drink for overweight and hyperlipidemic individuals.

The present invention relates to a nutraceutical composition for the prevention and / or treatment of obesity and / or overweight and / or the yo-yo effect in humans or animals, comprising a mixture of extracts of Chrysanthellum americanum and Hibiscus sabdariffa, or a single extract obtained from these two plants. The combination of these extracts allows for a synergistic effect that improves efficacy in regulating lipid metabolism and reducing fat accumulation in preadipocytes. Figure for the abstract: Fig. 1

The present invention relates to a GLP-1- / GIP- / amylin-receptor tri-agonist. This GLP-1- / GIP- / amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention provides methods of treating and / or managing obesity and / or overweight and methods of losing weight, which comprise administering to a subject N-[2-{[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3- triazol-2-yl)pyridine-2-carboxamide ("Compound A"), or an enantiomer or mixture of enantiomers, a tautomer, an isotopolog, a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a GLP-1 receptor agonist.

An extract of Akkermansia muciniphila BAA-835 is provided, comprising: providing a bacterial culture medium containing Akkermansia muciniphila BAA-835; centrifuging the bacterial culture medium to obtain a supernatant and a precipitate; extracting a portion of the supernatant with ethyl acetate to obtain an ethyl acetate aqueous layer; drying the ethyl acetate aqueous layer to obtain an aqueous ethyl acetate extract; extracting a remaining portion of the supernatant with n-hexane to obtain a n-hexane aqueous layer and a n-hexane organic layer; and drying the n-hexane aqueous layer and the n-hexane organic layer respectively to obtain the aqueous n-hexane extract and the organic n-hexane extract. Also provided is a method of the extract as described above for treating and preventing overweight or obesity disease, increasing GLP-1, lowering triglycerides, or combinations thereof.

The present invention relates to a nutraceutical composition for the prevention and / or treatment of obesity and / or overweight and / or the yo-yo effect in humans or animals, comprising a mixture of extracts of Chrysanthellum americanum and Hibiscus sabdariffa, or a single extract obtained from these two plants. The combination of these extracts produces a synergy that improves efficacy in regulating lipid metabolism and reducing fat accumulation in preadipocytes.

The present invention provides a dietary food, in particular a meal replacement in the form of bars, for weight-controlling diets, said dietary food comprising 6 wt.% or less than 6 wt.% digestible and energy-providing carbohydrates, a high content of non-metabolizable carbohydrates, and a protein content from 25 wt.% to 50 wt.%. The invention further provides a method for preparing such dietary food and its use in treating diseases connected with pathological overweight.

The present invention provides a GLP-1- / GIP- / amylin-receptor triple agonist having a balanced efficacy ratio across all three receptors and / or improved pharmacokinetic properties. The present invention also provides a pharmaceutical composition comprising such a GLP-1- / GIP- / amylin-receptor triple agonist, as well as its use as a medicine for the treatment of subjects with overweight, obesity, and associated comorbidities.

The present disclosure relates to a polypeptide analog or a derivative thereof, and a preparation method and use thereof, and particularly to an agonistic polypeptide analog or a derivative thereof of an insulin amyloid polypeptide receptor. The polypeptide analog or the derivative thereof provided by the present disclosure has good agonistic activity on the insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity, etc, at the same time, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as body weight abnormality, especially obesity and overweight.

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.